
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50M Financing
BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a […]